Get startedLog in
    Picture of Gensight Biologics SA logo

    SIGHT — Gensight Biologics SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapMomentum Trap
    All News

    Brief: GenSight Announces Publication Of Study Reporting Presence Of LUMEVOQ Vector DNA In Contralateral Eyes After Unilateral Injection

    Picture of Gensight Biologics SA logoGensight Biologics SA
    01/12/2021 06:38
    Dec 1 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * ANNOUNCES PUBLICATION OF NON-HUMAN PRIMATE STUDY REPORTING
PRESENCE OF LUMEVOQ® VECTOR DNA IN CONTRALATERAL EYES AFTER
UNILATERAL INJECTION
    * STUDY DEMONSTRATES CONTRALATERAL TRANSFER OF LUMEVOQ®
AFTER
UNILATERAL INJECTION
    * RESULTS SUGGEST MECHANISTIC EXPLANATION FOR BILATERAL
IMPROVEMENT OF VISUAL FUNCTION AMONG ND4-LHON PATIENTS
UNILATERALLY TREATED WITH LUMEVOQ

Source text for Eikon:  ID:nBw6c2R0va 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Gensight Biologics SA

    See all news